The STEP program trials with semaglutide (a GLP-1-only agonist) and the SURMOUNT trials with tirzepatide (dual GIP/GLP-1 agonist) represent the strongest weight loss efficacy data in the history of pharmacotherapy for obesity
But for a large number of patients, the medications fall short, fail entirely, or come with side effects that make long-term use impossible
Journal of Aerosol Medicine and Pulmonary Drug Delivery 28 (1), 5967 (2015)
[24] [13] As a precaution, seek medical advice if you notice a lump or swelling in your neck, difficulty swallowing, or persistent hoarseness
For each eligible study, two authors (MM and AN) independently extracted data, which was then reviewed by a third author (JV) using a piloted spreadsheet, in accordance with Cochrane Collaboration guidelines ( Where relevant data were missing, attempts were made to contact corresponding authors